Retatrutide vs. Mounjaro
Triple Agonist vs. Dual Agonist
Comparison of the established king (Mounjaro) versus the upcoming challenger (Retatrutide). Is 3 better than 2?
🔥 "Triple G" Agonist🧪 Clinical Trial Data🚀 Future Medicine
| Metric | Mounjaro | Retatrutide |
|---|---|---|
| Type | Dual Agonist (GLP-1/GIP) | Triple Agonist (GLP-1/GIP/Glucagon) |
| Max Weight Loss (Trial) | ~21% | ~24-26% (Preliminary) |
| Liver Fat Reduction | Significant | Near-total clearance |
| Status | FDA Approved | Phase 3 Trials |
Mounjaro: The Proven Winner
Mounjaro is currently available, FDA-approved, and has a massive safety dataset. It effectively balances appetite suppression and blood sugar control. For most people today, this is the "gold standard."
Retatrutide: The Future
The "Glucagon" component in Retatrutide actually *burns calories* by increasing metabolic rate, in addition to suppressing appetite. This "triple threat" mechanism explains the unprecedented weight loss numbers seen in trials.
Track Current & Future Meds
Shotlee is already updated to support Retatrutide tracking for researchers and future patients.
🚀 Download Shotlee Free